Thank you Zuess. All along I was awaiting reassurance from Dr. Harish. He reiterates what Br. BP is saying, and from the ARDS perspective alone, he seems more bulish than Dr. BP. Maybe as he was seeing the physical/visual health of the patients degrading, and then stabilized.

Quote:

---

“Such patients all too often seem to be recovering, but then crash and burn when their lungs are overwhelmed by an inflammatory reaction that makes breathing impossible, “says Dr. Seethamraju. “The FDA is concerned that there is no treatment for those people.”

---

Quote:

---

“By calming the overactive immune systems of these patients, leronlimab halted the inflammation and blood clotting that are so damaging to the lungs, liver and kidneys of severely ill COVID-19 patients,” said Dr. Seethamraju. All 10 patients had extremely high blood levels of CCL5, which are inflammatory molecules known as cytokines. This is why the extreme inflammatory response is known as the “cytokine storm.” Leronlimab interfered with those CCL5 molecules, preventing them from directing immune cells to swarm into and inflame the lungs and other organs.

---